Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Life Span After Alzheimer's Diagnosis: What Factors Matter MostLots of Napping Could Raise a Senior's Odds for Alzheimer'sIs It 'Pre-Alzheimer's' or Normal Aging? Poll Finds Many Americans UnclearMore Evidence That Education May Protect Against DementiaAHA News: These Three Risk Factors May Have the Biggest Impact on Dementia CasesAHA News: Traumatic Brain Injury May Raise Veterans' Long-Term Stroke RiskMore Years Playing Hockey, Higher Odds for CTE Linked to Head InjuryPandemic Caused Rise in Deaths of Alzheimer's PatientsStaying Fit May Keep Alzheimer's at BayConcussion's Impact on Memory, Thinking May Linger More Than a YearBrain Injuries May Be Driving Higher Death Rate for U.S. VeteransAHA News: Statistics Report Offers Snapshot of the Nation's Brain Health – And a Guide to Protecting ItKeeping Weight Stable Could Help Save Your BrainMedicare Proposes to Only Cover Alzheimer's Drug Aduhelm for Use in Clinical TrialsAduhelm: Will Medicare Cover the Controversial Alzheimer's Drug?More U.S. Seniors, Especially Women, Are Retaining Healthy Brains: StudyMaker Cuts Price of Controversial New Alzheimer's Drug in HalfCould Viagra Help Prevent Alzheimer's?Lifetime Spent With Epilepsy Ages the Brain, Study Finds'Mild Cognitive Impairment' in Older Age Often Disappears, Study FindsMore Years Playing Football, More Brain Lesions on MRI: StudyReminder Apps on Smartphones May Help in Early DementiaNeurologists' Group Issues Guidance to Families on Controversial Alzheimer's DrugTrial Begins of Nasal Vaccine for Alzheimer's DiseaseAlzheimer's Diagnosis May Come With Big Cost to Social LifeCould Estrogen Help Shield Women's Brains From Alzheimer's?Purrfect Pal: Robotic Cats May Help People With DementiaRight Amount of Sleep May Be Important in Early Alzheimer'sAHA News: Hearing Loss and the Link to DementiaDepression in Early Life May Up Dementia Risk LaterScientists Untangle Why Diabetes Might Raise Alzheimer's RiskTracking Key Protein Helps Predict Outcomes in TBI PatientsMIND Diet May Guard Against Alzheimer'sSigns of Early Alzheimer's May Be Spotted in Brain StemCould Cholesterol Help Drive Alzheimer's Disease?Most Alzheimer's Patients Wouldn't Have Qualified for Controversial Drug's Trial: StudyAHA News: What Are Researchers Doing to Stop Dementia?A Mentally Challenging Job Could Help Ward Off DementiaDirty Air, Higher Dementia Risk?An ALS Drug Shows Early Promise Against Alzheimer'sAHA News: Dementia Can Complicate Heart Recovery and TreatmentDeaths From Alzheimer's Far More Common in Rural AmericaCould COVID-19 Accelerate Alzheimer's Symptoms?Dementia Cases Will Nearly Triple Worldwide by 2050: StudyFDA Panel Advisor Who Panned New Alzheimer's Drug Speaks Out'Light Flash' Treatment Might Help Slow Alzheimer'sCleaning Up the Air Could Help Prevent Alzheimer'sLong-Term Outlook for Most With Serious Brain Injury Is Better Than ThoughtDrug Shows Promise in Easing Dementia-Linked PsychosisAHA News: Diabetes and Dementia Risk: Another Good Reason to Keep Blood Sugar in Check
Links
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Maker Cuts Price of Controversial New Alzheimer's Drug in Half

HealthDay News
by Robert Preidt and Robin Foster
Updated: Dec 20th 2021

new article illustration

MONDAY, Dec. 20, 2021 (HealthDay News) -- The maker of the pricey new Alzheimer's drug Aduhelm (aducanumab) said Monday it will slash the cost of its medication in half, effective Jan. 1, 2022.

The move follows widespread criticism of the drug's original $56,000-a-year price tag.

The reduction in the wholesale acquisition cost announced by Biogen means that the annual cost for a patient of average weight will be $28,200, the company said in a news release.

"Over the past several months, we have listened to the feedback of our stakeholders, and we are now taking important actions to improve patient access to Aduhelm," said Biogen CEO Michel Vounatsos.

"Too many patients are not being offered the choice of Aduhelm due to financial considerations and are thus progressing beyond the point of benefitting from the first treatment to address an underlying pathology of Alzheimer's disease," Vounatsos said in the release. "We recognize that this challenge must be addressed in a way that is perceived to be sustainable for the U.S. health care system."

Insurance coverage will affect the actual amount paid by patients.

The drug is meant to clear brain plaques believed to play a role in Alzheimer's, and the U.S. Food and Drug Administration approved the drug in June for patients with mild or early-stage symptoms.

However, Aduhelm's initial price has limited its use. It isn't being widely offered by medical centers and some insurers have complained about paying for it. Also, the price of Aduhelm has been pointed to as a major reason for planned premium increases for Medicare.

Last month, Medicare announced one of the largest increases ever in its Part B monthly premium for outpatient care, saying the premium would go from $148.50 to $170.10, starting in January. The agency said about half of that hike was due to the need for a contingency fund to cover Aduhelm because Medicare is expected to be one of the main payers for the drug.

"It is a critical time for the Alzheimer’s disease community as the Centers for Medicare and Medicaid Services [CMS] is considering the possibility of coverage of not only Aduhelm, but also this entire new class of Alzheimer's disease therapies," Vounatsos said. "We hope our actions today will facilitate patient access to these innovative Alzheimer's treatments."

Along with concerns about the price of Aduhelm, Alzheimer's patients taking the drug also have the added costs of regular testing and scans to monitor the progress of their disease during treatment, the Associated Press reported.

More information

Find out more about Aduhelm at the Alzheimer's Association.

SOURCES: Biogen, news release, Dec. 20, 2021; Associated Press




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net